Table 2.
Summary-of-findings table
| Outcome | Certainty of evidence | Effect estimate | |
|---|---|---|---|
| RR (95% CI) | Absolute difference, per 1000 | ||
| DOAC-based dual-pathway therapy vs triple-antithrombotic therapy in AF after PCI or medically-managed ACS | |||
| MACE | Moderate∗ | 1.12 (0.97–1.28) | 8 more (from 2 fewer to 19 more) |
| Death | Moderate∗ | 1.07 (0.88–1.30) | — |
| Stent thrombosis | Moderate∗ | 1.55 (1.02–2.36) | 4 more (from 0 to 9 more) |
| Major bleed | High | 0.62 (0.52–0.73) | 23 fewer (from 16 to 29 fewer) |
| OAC monotherapy vs OAC plus single antiplatelet in AF plus remote (> 1 y) ACS/PCI | |||
| MACE | Very low†,‡ | 0.91 (0.58–1.41) | — |
| Death | Very low†,‡ | 0.85 (0.37–1.92) | — |
| Stent thrombosis | Low‡ | 5.03 (0.24–104.37) | — |
| Major bleed | High | 0.66 (0.49–0.91) | 22 fewer (from 6 to 33 fewer) |
ACS, acute coronary syndrome; AF, atrial fibrillation; CI, confidence interval; DOAC, direct OAC; MACE, major adverse cardiovascular events; OAC, oral anticoagulation; PCI, percutaneous coronary intervention; RR, risk ratio.
∗
Rated down 1 category for serious imprecision.
†
Rated down 1 category for serious inconsistency.
‡
Rated down 2 categories for very serious imprecision.